NCT06705387View on ClinicalTrials.gov

Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE

PHASE2RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 23, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

March 31, 2027

Conditions
Eosinophilic Esophagitis
Interventions
BIOLOGICAL

Dupilumab

Subcutaneous injection of 300mg per week for 16 weeks.

DRUG

Fluticasone

Metered dose swallowed topical corticosteroid, given 1760mcg per day for 16 weeks.

Trial Locations (1)

80045

RECRUITING

Children's Hospital Colorado/University of Colorado School of Medicine, Aurora

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Colorado, Denver

OTHER